Thermo Fisher Scientific to acquire Mesa Biotech, gaining COVID-19 testing platform
Thermo Fisher Scientific to acquire Mesa Biotech, gaining COVID-19 testing platform Thermo Fisher Scientific will acquire San Diego molecular diagnostics company Mesa Biotech for approximately $450m in cash, with up to an additional $100m upon completion of certain milestones. Privately held Mesa Biotech has developed and commercialized a PCR-based rapid point-of-care testing platform available for detecting infectious diseases including SARS-CoV-2, Influenza A and B...
United States Thermo Fisher Life Sciences Solution Segment Clinical Laboratory Improvements Amendments Drug Administration Mesa Biotech Accula System
Source: biopharma-reporter.com